Last reviewed: May 16, 2026
Last updated: May 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Henry Meds is a telehealth platform offering weight management and metabolic health services through licensed providers. However, patients seeking alternatives should understand how different platforms vary in medication sourcing, personalization depth, and clinical infrastructure—factors that directly impact safety and treatment outcomes.
Choosing a GLP-1 provider involves more than convenience. It requires evaluating whether the platform supports precision wellness through biomarker assessment, genetic insights, and collaborative provider oversight. PlexusDx emphasizes this clinical-first approach to help patients and providers make data-informed decisions.
Understanding GLP-1 Provider Models and Sourcing
GLP-1 medications come from two primary sources: branded pharmaceutical products (Wegovy, Zepbound, Mounjaro, Ozempic) and 503A-compounded alternatives prepared by licensed pharmacies. Branded drugs undergo FDA approval; compounded medications are prepared in state-licensed facilities under pharmacy supervision but are not FDA-approved as finished products.
PlexusDx partners exclusively with 503A compounding pharmacies to provide semaglutide and tirzepatide at lower cost points than many branded alternatives. Understanding sourcing matters because availability, cost, and supply chain stability differ significantly between platforms offering branded versus compounded formulations.
Key Differences Between GLP-1 Providers: A Clinical Comparison
Not all GLP-1 platforms offer the same depth of clinical assessment, genetic testing, or dosing customization. The framework below highlights critical factors patients should evaluate when selecting a provider to support informed conversations with their healthcare team.
| Clinical Factor |
Consideration for Your Decision |
| Medication Sourcing |
Branded (FDA-approved) vs. 503A-compounded (cost-effective, pharmacy-supervised) |
| Genetic or Biomarker Testing |
Optional genetic predisposition assessment in peptide pathways to contextualize treatment approach |
| Provider Model |
Telehealth-only vs. hybrid (telehealth with in-person option); physician oversight quality |
| Dosing Protocols |
Standardized vs. personalized titration based on individual response and biomarker context |
| Support and Monitoring |
Frequency of provider check-ins, side effect management, access to nutritional counseling |
| Cost and Insurance |
Monthly pricing, insurance acceptance, financial assistance programs available |
The Role of Genetic Insights in Personalizing GLP-1 Treatment
Recent research identifies genetic variants in GLP-1 receptor pathways, GIPR signaling, and appetite regulation genes (FTO, MC4R) that may influence individual metabolic response. These predispositions do not determine treatment outcome but may help providers contextualize dosing and protocol selection during clinical conversations.
PlexusDx offers a Precision Peptide Genetic Test examining key variants in GLP-1 pathway genes. This assessment is designed to support a more personalized conversation between patient and provider—revealing predispositions that may inform which compounded formulation, starting dose, or titration schedule aligns with individual biology.
Safety, Eligibility, and When to Seek Provider Evaluation
GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, or uncontrolled diabetes. A thorough medical history and provider assessment are essential before starting any GLP-1 therapy, whether branded or compounded.
Side effects—nausea, vomiting, constipation, and dehydration—occur frequently early in treatment. Providers experienced in GLP-1 management can adjust dosing, timing, and patient education to minimize burden. Choose a platform where provider accessibility and side effect support are prioritized, not afterthoughts. Always disclose all medications and medical history during your initial consultation.
How PlexusDx Supports a More Personalized Approach
PlexusDx genetic testing may help provide context for how individual peptide pathway variants influence metabolic response to GLP-1 therapy. The Precision Peptide Genetic Test examines predispositions in GLP1R, GIPR, FTO, and MC4R genes—key regulators of appetite, insulin secretion, and energy homeostasis. Should be interpreted with a qualified healthcare provider as part of a comprehensive assessment.
The genetic test does not predict exact medication response or guarantee outcomes. Instead, it reveals individual predispositions in peptide signaling pathways that may inform personalized treatment conversations. For example, certain FTO variants associate with greater baseline appetite dysregulation, potentially contextualizing why some individuals benefit from GLP-1 earlier in their metabolic journey.
This information can support a more informed conversation with your provider about which compounded GLP-1 formulation, starting dose, or titration schedule may align with your genetic and clinical profile. When combined with biomarker assessment (lipids, glucose, inflammatory markers) and detailed medical history, genetic context contributes to precision-wellness decision-making.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between Henry Meds and other GLP-1 providers?
Henry Meds is a telehealth platform offering standardized weight management protocols. Alternatives vary in medication sourcing (branded vs. compounded), personalization depth, genetic testing availability, and provider accessibility. No single model suits everyone—your choice depends on clinical priorities and budget.
Are compounded GLP-1 medications as safe as branded versions?
503A-compounded semaglutide and tirzepatide are prepared in state-licensed pharmacies under pharmacy supervision. They are not FDA-approved as finished products but follow pharmaceutical-grade standards. Safety depends on pharmacy quality, proper storage, and medical oversight.
How much do compounded GLP-1 medications cost through PlexusDx?
Compounded semaglutide injections range $149/mo; oral semaglutide starts at $249/mo. Compounded tirzepatide injections cost $249/mo. Oral tirzepatide ranges $279/mo depending on dose. The Precision Peptide Genetic Test is $99 (add-on) or $298 (standalone).
Can genetic testing predict how well I'll respond to a GLP-1 medication?
No. The Precision Peptide Genetic Test reveals predispositions in peptide pathway genes, not guaranteed medication response. Genetic variants contextualize individual metabolic biology and may inform personalized dosing discussions with your provider, but outcomes depend on many factors beyond genetics.
What should I look for when comparing GLP-1 providers?
Evaluate medication sourcing (branded vs. compounded), provider credentials and availability, genetic or biomarker testing options, side effect support, pricing, and insurance acceptance. Ask whether the platform supports personalized dosing versus standardized protocols. A thorough initial consultation is essential.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Healthon Tirzepatide: Biomarker Context and Provider Selection
FuturHealth vs Ro: Clinical Evidence for GLP-1 Telehealth Selection